期刊文献+

配偶淋巴细胞体外诱生免疫及地屈孕酮治疗不明原因反复自然流产的疗效比较及对围产期母婴的影响 被引量:14

Evaluation of curative effect and safety of treatments for unexplained recurrent spontaneous abortion by paternal lymphocyte in vitro induced immunization and dydrogesterone
原文传递
导出
摘要 目的:探讨配偶淋巴细胞体外诱生免疫联合地屈孕酮治疗对不明原因反复自然流产(URSA)患者再次妊娠结局及对孕妇围产期并发症的发生和新生儿发育的影响。方法:随访分析254例URSA患者,其中A组84例接受配偶淋巴细胞体外诱生免疫治疗;B组86例接受地屈孕酮治疗;C组84例接受体外诱生免疫联合地屈孕酮治疗;比较3组患者接受治疗后的再次妊娠成功率,以及围产期孕产妇的情况和新生儿的发育。结果:3组患者再次妊娠成功率分别为89.3%、70.9%和92.8%。B组低于其他各组,且差异有统计学意义(P<0.05)。3组患者新生儿的分娩孕周无统计学差异(P>0.05);足月新生儿出生体质量及身长组间无统计学差异(P>0.05);各组与正常参照标准比较差异无统计学意义(P>0.05)。3组间围产期妊娠并发症及新生儿畸形的发生率与流行病学调查数据比较无统计学差异(P>0.05)。结论:与单用地屈孕酮治疗比较,配偶淋巴细胞体外诱生免疫,或诱生免疫联合地屈孕酮治疗显著增加URSA患者再次妊娠的成功率;3种方法治疗均不影响新生儿生长发育;与正常妊娠相比,3种治疗均不增加孕妇围产期妊娠并发症与新生儿畸形率。 Objective: To evaluate the efficacy and safety of treatments of unexplained recurrent spontaneous abortion (URSA) by paternal lymphocyte in vitro induced immunization combined with dydrogesterone on the pregnant outcome as well as on the influence of perinatal complication for the pregnant woman and neonatal development. Methods: A total of 254 URSA patients were followed up and analyzed. Among them, 84 cases treated with paternal lymphocyte induced immunization were defined as group A; 86 cases treated orally with dydrogesterone were :recruited as group B; 84 cases who accepted therapy by lymphocyte induced immunization combined with dydrogesterone were classified as group C. The pregnancy outcome after treatment as well as the maternal situation and neonatal development were recorded and compared among three groups. Results: The pregnancy success rate of groups A, B, C was 89.3%, 70.9% and 92.8%, respectively, which was significantly lower in group B than in other groups (P〈0.05). There was no significant difference (P〉0.05) of delivery gestational week of the newborns among the three groups. Full-term birth weight and body length among the three groups had no significant difference (P〉0.05). Comparison of newborn birth weight and body length with normal reference standards showed no significant difference (P〉0.05). Conclusion: Paternal lymphocyte induced immunization or induced immunization combined with dydrogesterone can significantly improve the pregnancy outcome of URSA compared with only given oral dydrogesterone alone. All the three methods had no adverse effect on the occurrence of both perinatal complication and growth of newborns.
出处 《生殖与避孕》 CAS CSCD 北大核心 2015年第12期834-839,共6页 Reproduction and Contraception
基金 上海卫生系统先进适宜技术推广项目(2013SY034) 国家自然科学基金面上项目(31171437)
关键词 不明原因反复自然流产(URSA) 地屈孕酮 配偶淋巴细胞体外诱生免疫 unexplained recurrent spontaneous abortion (URSA) dydrogesterone patemal lymphocyte in vitro induced immunization
  • 相关文献

参考文献14

  • 1Larsen EC, Chrisfiansen OB, Kolte AM, et al. New insights into mechanisms behind miscarriage. BMC Med, 2013, 11 : 154.
  • 2Tien JC, Tan TYT. Non-surgical interventions for threatened and recurrent miscarriages. Singapore Med J, 2007, 48(12): 1074-90.
  • 3刘娟,吴和英,谭宗建,张红云,张勇,邓丽萍(编辑).反复自然流产患者封闭抗体检测及淋巴细胞免疫治疗的临床效果[J].医学临床研究,2012,29(8):1488-1490. 被引量:10
  • 4杨菊华,庞汝彦,钱军程,刘鸿雁,覃民,张莹,郭静,唐元红,冯碧波,翟建军,何川.畸高的中国剖宫产率:问题与对策[J].人口与发展,2012,18(5):36-39. 被引量:32
  • 5卫生部妇幼保健与社区卫生司.中国儿童生长标准与生长曲线.上海:第二军医大学出版社,2009:35-140.
  • 6Taylor CG, Faulk WP. Prevention of recurrent abortion with leucocyte transfusions. Lancet, 1981, 2(8237):68-70.
  • 7李大金,李超荆.原发性反复自然流产的白细胞免疫治疗[J].生殖与避孕,1995,15(6):457-458. 被引量:15
  • 8Gruber C J, Huber JC. The role of dydrogesterone in recurrent (habitual) abortion. J Steroid Biochem Mol Biol, 2005, 97 (5):426-30.
  • 9Joachim R, Zenclussen AG, Polgar B, et al. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response. Steroids, 2003, 68(10-13):931-40.
  • 10Szekeres-Bartho J, Balasch J. Progestogen therapy for recurrent miscarriage. Hum Reprod Update, 2008, 14(1): 27-35.

二级参考文献21

共引文献59

同被引文献108

引证文献14

二级引证文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部